Lyophilization: A Primer - Optimized freeze-drying cycles can offer scientific and business advantages. - BioPharm International

ADVERTISEMENT

Lyophilization: A Primer
Optimized freeze-drying cycles can offer scientific and business advantages.


BioPharm International
Volume 26, Issue 3, pp. 46-51


Katriona Scoffin
Freeze drying, or lyophilization, is a stabilization method that is widely used in the pharmaceutical industry for drugs, vaccines, antibodies, and other biological material. Because the product is dried without excessive heating, proteins and other products that would be thermally denatured can be successfully preserved without loss of activity.

Freeze-dried products have a very high surface area, which enables them to be reconstituted quickly. This quick reconstitution is particularly important in the case of emergency vaccines and antibodies, which need to be administered as soon as possible.

Every formulation has different freeze-drying characteristics and, therefore, different processing requirements. To ensure cycles are both robust and efficient, they should be tailor-made for each formulation. Failure to do so can lead to inconsistent dryness across samples, reduced stability during storage, and reduced activity on rehydration.

There are three main business advantages of optimizing a product's lyophilization cycle:
  • Financial gain: optimal lyophilization cycles use only the energy and time required, shortening process time and increasing product throughput.
  • Product excellence: a well-dried product exhibits a long shelf life and maximum activity on rehydration.
  • Quality and regulatory assurance: consistency throughout batches is assured and regulatory submissions are completed with the inclusion of lyophilization cycle data.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here